Roche Venture Fund Portfolio

Our current portfolio includes more than 30 companies. We seek to add value to our companies and create highly valuable business enterprises.

Aligos
We discover targeted antiviral therapies for chronic hepatitis B (CHB), COVID-19, and optimized therapeutics for Nonalcoholic Steatohepatitis (NASH).
Bonum Therapeutics
Bonum Therapeutics is focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines.
Civi Biopharma
Focused on creating novel therapies against diseases where the unmet medical need exists.
Cour
COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease.
DiogenX
DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of diabetic patients around the world.
Enliven Therapeutics
We are a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors to help patients with cancer live longer and better.
Enthera
First-in-class therapeutics for auto-immune disorders
Entrada
Overcoming the challenge of intracellular target access to transform the treatment of devastating diseases
EpiBiologics
Advancing bispecific antibodies designed to selectively degrade disease-causing extracellular proteins.
Forcefield Therapeutics
Revolutionising the treatment of heart attacks.
Freenome
Freenome is a biotechnology company based in South San Francisco that has pioneered the most comprehensive multiomics platform for early cancer detection with a simple blood test.
Glycoera
GlycoEra has developed a game-changing protein engineering and production platform to build a high-value pipeline of medicines.
Kumquat Biosciences
Developing innovative therapies to bring about sustainable and life-changing benefits to cancer patients.
Merge Therapeutics
Merge Therapeutics is developing first-in-class multispecific antibodies for a variety of immune-mediated diseases to our portfolio
Minoryx
Minoryx is focused on the discovery and development of novel treatments for severe, orphan diseases of the central nervous system with high unmet medical need.
Mironid
Mironid® is developing novel small-molecule therapeutics that directly target the central signalling mechanism that drives ADPKD.
Mission Therapeutics
Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
NMD Pharma
NMD Pharma discovers and develops novel therapeutics for neuromuscular diseases.
Noema Pharma
Developing therapies to help both orphan and larger patient populations with conditions of the brain and nervous system live their lives to the fullest.
Receptive Bio
Receptive Bio is advancing next-generation receptor-mediated shuttles to unlock therapeutic delivery to the brain and beyond
River3Renal
Developer of novel therapies intended to cure orphan diseases.
Sarepta Therapeutics
We are focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases
SpliceBio
SpliceBio is a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes.
Tempest Therapeutics
Tempest Therapeutics is developing first-in-class small molecule product candidates with broad potential benefit to patients.
Vivet Therapeutics
Vivet Therapeutics is a clinical-stage emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases.